Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Date:12/3/2009

SAN FRANCISCO, Dec. 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looki
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... key challenges in the development of quantum technologies has ... a paper published today (28 October) in Nature ... to make a new type of flexibly designed microscopic ... high-precision sensors and specialised superfast computers, often depend on ... for trapping these tiny particles are hugely problematic because ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014 ... in the recent Ebola concern in the ... for the virus.  The healthcare market researcher said the ... of in vitro diagnostic tests for the detection of ... sensitivity has proved useful.  Kalorama routinely assess the IVD ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... MANASQUAN, N.J., April 7, 2008 BioSpace, the ... career fair company,will host a Private Label Career ... The event will take place at the Hanover ... 7 pm., (Logo: http://www.newscom.com/cgi-bin/prnh/20080222/CLF013LOGO ), ...
... to advance collaborative research worldwide, HUNTSVILLE, ... Inc.,announced today that leading research institutions, the ... the University of,Queensland, and the Biotech Research ... of Copenhagen have recently purchased access to ...
... found that the,Replikin Count(TM) of the H1N1 strain of ... highest level since the 1918 H1N1,pandemic (p value less ... strain, indicating rapid replication of the virus, is an ... of the specific,strain. The current increase appears to be ...
Cached Biology Technology:BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey 2Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 2Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland 3H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
(Date:10/29/2014)... City on September 19, 2014, leading geneticist and humanitarian ... Genome Sciences and Medicine at the University of Washington ... Tel Aviv University, was awarded the 2014 Lasker-Koshland Special ... her honorary degree from TAU, Prof. King was the ... and for the past 18 years she has been ...
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2
... 2013 Oxidative stress is a primary villain in ... heart failure to Alzheimer,s disease, Amyotrophic Lateral Sclerosis and ... The Scripps Research Institute (TSRI) have found that blocking ... destruction of neurons associated with these neurodegenerative diseases, suggesting ...
... biofuel crops such as miscanthus, whose high yields have ... corn in producing ethanol, are now shown to have ... nitrogen in the environment. In a 4-year University of ... species to typical corn-corn-soybean rotations, each of the perennial ...
... in the part of the brain linked to spatial awareness. ... room, we can go into it with our eyes shut and ... we map out how to get from one place to another ... in electrical activity, do not do so by talking directly to ...
Cached Biology News:Scripps Florida scientists uncover potential drug target to block cell death in Parkinson's disease 2Lower nitrogen losses with perennial biofuel crops 2Lower nitrogen losses with perennial biofuel crops 3Rhythms in the brain help give a sense of location, study shows 2